Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Beats Estimates By $0.02 EPS

Sana Biotechnology (NASDAQ:SANA) announced its quarterly earnings data on Monday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02, FiscalAI reports.

Sana Biotechnology Stock Up 2.6%

SANA traded up $0.09 on Monday, reaching $3.61. The company had a trading volume of 2,419,104 shares, compared to its average volume of 3,144,554. The stock has a 50-day moving average price of $3.30 and a 200-day moving average price of $3.48. The stock has a market capitalization of $1.00 billion, a PE ratio of -3.88 and a beta of 2.16. Sana Biotechnology has a 1 year low of $2.61 and a 1 year high of $6.55.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SANA. Wedbush lifted their price target on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Weiss Ratings upgraded shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Rodman & Renshaw assumed coverage on shares of Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Institutional Trading of Sana Biotechnology

Large investors have recently made changes to their positions in the company. Virtu Financial LLC increased its position in Sana Biotechnology by 189.4% during the fourth quarter. Virtu Financial LLC now owns 119,312 shares of the company’s stock worth $486,000 after buying an additional 78,088 shares during the period. Invesco Ltd. boosted its stake in Sana Biotechnology by 24.1% during the 4th quarter. Invesco Ltd. now owns 561,835 shares of the company’s stock worth $2,287,000 after purchasing an additional 109,078 shares during the period. XTX Topco Ltd grew its position in Sana Biotechnology by 9.9% during the 4th quarter. XTX Topco Ltd now owns 117,376 shares of the company’s stock worth $478,000 after purchasing an additional 10,581 shares during the last quarter. VARCOV Co. acquired a new position in Sana Biotechnology in the fourth quarter valued at $264,000. Finally, Virtus Investment Advisers LLC boosted its stake in shares of Sana Biotechnology by 15.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 51,756 shares of the company’s stock worth $211,000 after buying an additional 6,958 shares during the period. 88.23% of the stock is owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.